CG Oncology’s adenovirus-based oncolytic viral immunotherapy has shown significant improvements in a Phase III non-muscle invasive bladder cancer (NMIBC) trial.

In the PIVOT-006 trial (NCT06111235), cretostimogene grenadenorepvec was investigated in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC, following complete tumour resection (TURBT). PIVOT-006 enrolled 367 patients across around 90 sites in the US and Canada.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Following the data announcement, the company, listed on the Nasdaq exchange under the ticker CGON, saw its stock rise by 23.7% at market open on 16 November, opening at $92 from $74.40 at market close on 13 November.

Compared to those in the control arm, who received no intervention following resection, cretostimogene resulted in a 68% reduction in the risk of recurrence with a hazard ratio (HR) of 0.32. The median follow-up was 17 months as of October 26, 2026.

Cretostimogene was generally well tolerated, with safety results consistent with those reported in previous studies, with no Grade 3 or greater treatment-related adverse events (TRAEs) and no treatment-related discontinuations reported in the study.

While the control arm had no intervention, patients did receive surveillance, and for those who saw recurrence following TURBT, they were offered treatment with cretostimogene as per the treatment schedule in the investigational arm, becoming an extension arm in the study.

Arthur Kuan, chairman and CEO of CG Oncology, said: “The unparalleled PIVOT-006 results represent a defining milestone for CG Oncology and position cretostimogene as the first and only therapeutic candidate to demonstrate a significant recurrence benefit in a pivotal Phase III trial in intermediate-risk and HG Ta NMIBC.”

Based on the data and feedback from the US Food and Drug Administration (FDA), CG Oncology is looking to submit a broadened biologics licence application (BLA) for the gene therapy, beyond the initial application for its use in BCG-unresponsive NMIBC, to also include intermediate-risk and HG Ta NMIBC, with the application set to be submitted in the second quarter of 2027.

The original BLA was due to be filed for BCG-unresponsive patients, focused on those with CIS with or without papillary tumours, and included patients with high-grade papillary-only disease. This BLA was based on the pivotal BOND-003 trial (NCT04452591).

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy which received FDA fast track and breakthrough therapy designations for BCG-unresponsive NMIBC.

Other companies have seen recent success in NMIBC, including enGene, which saw a 62% complete response (CR) rate in a Phase III trial of detalimogene voraplasmid after six months of treatment. Detalimogene voraplasmid is also an investigational, non-viral, non-integrating intravesical gene therapy.

UroGen also gained approval for Zusduri (mitomycin) in low-grade, intermediate-risk NMIBC. In addition, there are a number of drugs, including MSD’s Keytruda, which are in Phase III trials, paving the way for a much broader treatment landscape.

The bladder cancer market across the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, China, and Japan) is projected to grow from $3bn in 2023 to $16bn in 2033, at a compound annual growth rate (CAGR) of 18%, driven by an increasing incidence of bladder cancer and a wave of therapeutic innovation across both NMIBC and muscle-invasive bladder cancer (MIBC) segments, according to a report by GlobalData, the parent company of Clinical Trials Arena.

Analysts believe that the approval of novel intravesical therapies in NMIBC and antibody-drug conjugates in MIBC is transforming the market.